Beyond typing and grading: target analysis in individualized therapy as a new challenge for tumour pathology.
In order to bring about its beneficial effects in oncology, targeted therapy depends on accurate target analysis. Whether cells of a tumour will be sensitive to a specific treatment is predicted by the detection of appropriate targets in cancer tissue by immunohistochemistry or molecular methods. In most instances this is performed by histopathologists. Reliability and reproducibility of tissue-based target analysis in histopathology require novel measures of quality assurance by internal and external controls. As a model for external quality assurance in targeted therapy an annual inter-laboratory trial has been set up in Germany applying tissue arrays with up to 60 mammary cancer samples which are tested by participants for expression of HER2/neu and steroid hormone receptors.
Kreipe
Hans H
HH
Institut für Pathologie der Medizinschen, Hannover, Germany.
von Wasielewski
Reinhard
R
D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D009369:Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011987:Receptors, Steroid / Q000032:analysis*; D046888:Tissue Array Analysis
D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011987:Receptors, Steroid